source
- Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…
- Veradermics reports positive Phase 3 results for oral baldness pillVeradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo. The dru…